Compare Cigna Corp (CI) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cigna Corp vs McKesson Corporation — how do they compare? Cigna Corp trades at $304.29 (market cap $80.25B), while McKesson Corporation trades at $807.61 (market cap $94.06B). The key difference: McKesson Corporation is the larger of the two by market cap, and Cigna Corp pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| CI | MCK | |
|---|---|---|
Market Cap | $80.25B | $94.06B |
Sector | Health | Health |
52-Week High | $311.00 | $995.69 |
52-Week Low | $244.41 | $659.01 |
Enterprise Value | $103.35B | $98.70B |
Dividend Yield | 2.06% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cigna (CI) trades at $304.50, up 3.76% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q1 2026 EPS of $7.79 exceeding the $7.60 estimate. Valuation metrics appear attractive with a P/E of 12.91 and P/S of 0.29. Recent news highlights strategic AI investments in pharmacy services and positive sector sentiment.
The investment case centers on undervaluation, earnings momentum, and dividend yield, though risks include regulatory challenges and moderating cash flow. With a consensus price target of $339.82 implying 11.6% upside, Wall Street maintains a bullish stance, but investors should weigh execution risks against growth initiatives.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cigna Corp
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM services were greatly expanded by its 2018 merger with Express Scripts and are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, but it also operates in government programs, such as Medicare Advantage. The company operates mostly in the U.S. with 15 million medical members covered as of the end of 2020, but its services extend internationally, covering another 2 million people.
Read more on CI →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
